title: [Treatment of malignant adrenal cortex carcinoma].
abstract: UNCOMMON MALIGNANCY: Adrenocortical carcinoma is a very rare malignancy with poor prognosis. Median survival ranges from 12 to 25 months. Most clinicians recommend aggressive surgical management of either local or recurrent and metastatic disease. ANTICORTISOL AGENTS: Mitotane, the most tested agent against inoperable and metastatic adrenocortical carcinoma, procures overall response rates of 20 to 25%, but recent data do not support its use in the adjuvant setting.
  
  
  METHODS
  The efficacy of cytotoxic chemotherapy is low but new agents or associations (with platinum salts), new concepts (dose-intensification, MDR (the chemoresistance gene) reversing agents) may be useful and five some hope in this difficult disease.
  The role of radiation therapy must be developed.
authors.affiliation: Service de Médecine interne, Hôpital de Hautepierre, CHU de Strasbourg.
authors.forename: E
authors.initials: E
authors.lastname: Andrès
authors.forename: F
authors.initials: F
authors.lastname: Grunenberger
authors.forename: J E
authors.initials: JE
authors.lastname: Kurtz
authors.forename: B
authors.initials: B
authors.lastname: Goichot
authors.forename: P
authors.initials: P
authors.lastname: Dufour
authors.forename: J L
authors.initials: JL
authors.lastname: Schlienger
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D010166:Palliative Care
chemical_list: D000970:Antineoplastic Agents